HUTCHMED (China) Limited — Form 6-K
Reporting period: Month of September 2026; filed September 28, 2026. The company is a foreign private issuer that files annual reports on Form 20-F.
Business context
The filing identifies an accompanying press release concerning initiation of a global trial of HMPL-A830, described as a KRAS-EGFR-antibody conjugate therapy, in patients with solid tumors. The supplied filing text does not include trial design, enrollment, timing, or other development details.
Financial results and liquidity
This filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparable-period figures.
Outlook, risks, and contingencies
No financial guidance, management commentary, risk disclosures, contingencies, or unusual financial items are provided in the supplied text.
Investor facts to verify
- Review Exhibit 99.1 for the full press release and details of the HMPL-A830 global trial.
- Verify the trial’s scope, timeline, and any disclosed development or funding implications; these are not stated in the supplied text.